Table 7.
Longitudinal presentation of analyte data post-ERT (baseline, 12, 24, and 36 weeks).
| Comparisons versus baseline | |||
|---|---|---|---|
| Week 12 (p < 0.01)* | Week 24 (p < 0.01) | Week 36 (p < 0.001) | |
| Increased over baseline | Apoliprotein CIII | Alpha-1-antitrypsin | Alpha-1-antitrypsin |
| MCP-1 | Apolipoprotein CIII | Apolipoprotein CIII | |
| MMP-2 | Complement 3 | Complement 3 | |
| Thrombopoietin | Endothelin-1 | MMP-2 | |
| Fibrinogen | IgM | ||
| MCP-1 | Fibrinogen | ||
| MIP-1 alpha | |||
| MMP-2 | |||
| Decreased over baseline | Alpha-2 macroglobulin | IL-4 | CD40 |
| SGOT | IL-13 | SGOT | |
| VCAM-1 | IL-1 alpha | Apoliprotein A1 | |
| SGOT | |||
| VCAM-1 | |||
| Comparison between treatment weeks | |||
| Week 12 vs. 24 (p < 0.05) | Week 12 vs. 36 (p < 0.01) | Week 24 vs. 36 (p < 0.05) | |
| Increased over time | Alpha-1-antitrypsin | Alpha-1-antitrypsin | Complement 3 |
| Apolipoprotein H | Apolipoprotein H | ||
| Complement 3 | Complement 3 | ||
| Endothelin-1 | Endothelin-1 | ||
| IgM | IGF-1 | ||
| IgA | IgM | ||
| MIP-1 alpha | Serum amyloid P | ||
| Serum amyloid P | TNF-alpha | ||
| von Willebrand Factor | |||
| Decreased over time | Alpha-fetoprotein | Apolipoprotein A1 | CD40 |
| Fatty acid binding protein | CD40 | ||
| IL-3 | IL-3 | ||
| IL-4 | |||
| IL-7 | |||
| IL-13 | |||
| Thrombopoietin | |||
*T-tests were performed at a variety of different p-values including p < 0.05, p < 0.01, and p < 0.001. The significance level that gave the best separation between groups is reported.